2. Search Result
Search Result
Results for "

Carboxypeptidase inhibitor

" in MedChemExpress (MCE) Product Catalog:

23

Inhibitors & Agonists

3

Peptides

2

Natural
Products

1

Recombinant Proteins

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100788
    2-PMPA
    5 Publications Verification

    2-(Phosphonomethyl)pentanedioic acid

    		 Carboxypeptidase Neurological Disease
    2-PMPA (2-(Phosphonomethyl)pentanedioic acid) is a glutamate carboxypeptidase II (GCPII) inhibitor with an IC50 of 0.0003 μM. 2-PMPA shows low blood-brain barrier penetration. 2-PMPA sodium blocks the hydrolysis of NAAG, regulates glutamate levels in the brain and neurovascular coupling. 2-PMPA is applicable to the research of neurological diseases .
    2-PMPA
  • HY-19414
    MLN-4760
    Maximum Cited Publications
    24 Publications Verification

    		 Angiotensin-converting Enzyme (ACE) Cardiovascular Disease
    MLN-4760 is a potent and selective human ACE2 inhibitor (IC50, 0.44 nM), with excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM).
    MLN-4760
  • HY-W096171
    D-Dopa

    3-Hydroxy-D-tyrosine

    		 Carboxypeptidase Infection Neurological Disease
    D-Dopa (3-Hydroxy-D-tyrosine) is a potent, orally active, non-competitive and allosteric inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 200 nM. D-Dopa elevates brain dopamine and produce turning behavior in rats. D-Dopa inhibit severe fever with thrombocytopenia syndrome (SFTS) virus infection. D-Dopa can be used for neurological disease and virus infection research .
    D-Dopa
  • HY-70005
    CPA inhibitor
    3 Publications Verification

    Carboxypeptidase inhibitor

    		 Carboxypeptidase Wnt β-catenin Inflammation/Immunology
    CPA inhibitor (Compound 5) (Carboxypeptidase inhibitor) is an orally active competitive carboxypeptidase A (CPA) inhibitor with a Ki value of 0.32 μM. CPA inhibitor blocks the activity of carboxypeptidase A3 (CPA3). CPA activator activates the Wnt/Lrp6/β-catenin signaling pathway. CPA inhibitor reduces epithelial damage. CPA inhibitor is applicable to research related to inflammatory bowel disease, including ulcerative colitis and Crohn's disease .
    CPA inhibitor
  • HY-100788C
    2-PMPA sodium
    5 Publications Verification

    2-(Phosphonomethyl)pentanedioic acid sodium

    		 Carboxypeptidase Neurological Disease
    2-PMPA (2-(Phosphonomethyl)pentanedioic acid) sodium is a glutamate carboxypeptidase II (GCPII) inhibitor with an IC50 of 0.0003 μM. 2-PMPA sodium shows low blood-brain barrier penetration. 2-PMPA sodium blocks the hydrolysis of NAAG, regulates glutamate levels in the brain and neurovascular coupling. 2-PMPA sodium is applicable to the research of neurological diseases .
    2-PMPA sodium
  • HY-W704574
    Mergetpa

    		Carboxypeptidase Bradykinin Receptor Interleukin Related Cardiovascular Disease Metabolic Disease
    Mergetpa is a reversible Arg-carboxypeptidase inhibitor with high affinity. Mergetpa reduces B1R. Mergetpa blocks the overexpression of IL-1β protein and mRNA in glucose-fed rats. Mergetpa significantly increases the expression of IL-1β protein in the renal cortex. Mergetpa is used to block the conversion of kinins and B2 receptor antagonists into metabolites lacking the C-terminal arginine. Mergetpa inhibits the time-dependent enhancement of the response of isolated rabbit aorta to bradykinin. Mergetpa preserves the chemotactic activity of full-length SDF-1α on cells. Mergetpa reverses hyperglycemia, excessive weight gain, elevated levels of oxidative stress markers and overexpression of inflammatory markers in glucose-fed rats .
    Mergetpa
  • HY-W044764
    2-Benzylsuccinic acid
    1 Publications Verification

    DL-Benzylsuccinic acid

    		 Carboxypeptidase Neurological Disease Metabolic Disease
    2-Benzylsuccinic acid (DL-Benzylsuccinic acid) is an orally active carboxypeptidase A and Nna1 inhibitor. 2-Benzylsuccinic acid reduces cold hyperalgesia. 2-Benzylsuccinic acid can be used for the researches of neuropathic pain, non-alcoholic steatohepatitis .
    2-Benzylsuccinic acid
  • HY-177760
    PrCP-7414

    		Carboxypeptidase Apoptosis Akt Cancer
    PrCP-7414 is a prolyl carboxypeptidase (PRCP) inhibitor. PrCP-7414 blocks PRCP-mediated activation of the IGF1R/HER3 signaling pathway and subsequent AKT activation. PrCP-7414 exhibits pro-apoptotic, anti-tumor and synergistic cytotoxic activities, and inhibits the proliferation and survival of triple-negative breast cancer cells. PrCP-7414 can be used for the research of breast cancer .
    PrCP-7414
  • HY-70003
    Carboxypeptidase G2 (CPG2) Inhibitor

    CPG2 inhibitor

    		 Carboxypeptidase Cancer
    Carboxypeptidase G2 (CPG2) Inhibitor is a novel CPG2 inhibitor with an Ki of 0.3 μM. Carboxypeptidase G2 (CPG2) Inhibitor effectively neutralizes the CPG2 activity in non-tumor sites, allowing for earlier administration of the drug and forming a complementary strategy with antibody clearance strategies. Carboxypeptidase G2 (CPG2) Inhibitor can be used for the study of antibody-directed enzyme prodrug therapy (ADEPT) .
    Carboxypeptidase G2 (CPG2) Inhibitor
  • HY-103345
    2-MPPA

    GPI-5693

    		 Carboxypeptidase Neurological Disease Cancer
    2-MPPA (GPI-5693) is an orally active and selective glutamate carboxypeptidase II (GCP II; PSMA) inhibitor with an IC50 of 90 nM .
    2-MPPA
  • HY-148542
    EpoY

    SD-142

    		 Endogenous Metabolite Cardiovascular Disease Cancer
    EpoY (SD-142) acts as an irreversible inhibitor of the brain's primary tubulin tyrosine carboxypeptidase (TCP), a complex formed by vasohibin-1 (VASH1) and the small vasohibin binding protein (SVBP). By inhibiting TCP with an IC50 value of approximately 500 nM, EpoY effectively decreases levels of detyrosinated alpha-tubulin, which is crucial for microtubule dynamics and neuronal differentiation. This inhibition leads to significant differentiation defects and has been linked to underlying issues associated with cancer and cardiomyopathies.
    EpoY
  • HY-103344
    ZJ43

    		Aminopeptidase Carboxypeptidase mGluR Neurological Disease
    ZJ43 is a NAAG peptidase inhibitor and glutamate carboxypeptidase II/III (GCP II/III) inhibitor with human GCP II IC50 of 2.4 nM and Ki of 0.8 nM. ZJ43 blocks N-acetylaspartylglutamate hydrolysis, elevates extracellular N-acetylaspartylglutamate levels, and activates group II metabotropic glutamate receptors (mGluR). ZJ43 can be used for the research of schizophrenia, inflammatory pain, neuropathic pain, and traumatic brain injury .
    ZJ43
  • HY-122369
    Histargin

    		Carboxypeptidase Metabolic Disease
    Histargin is a selective carboxypeptidase B inhibitor with an IC50 of 17 μg/mL and a Ki of 30 μM. Histargin exerts competitive inhibition with substrate, with inhibitory activity abolished by metal cations. Histargin shows no significant inhibitory activity against carboxypeptidase A, aminopeptidase A, or aminopeptidase B .
    Histargin
  • HY-123733
    MIP-1095

    RPS-001

    		 PSMA Others Cancer
    MIP-1095 potently inhibits the glutamate carboxypeptidase activity of PSMA (Ki =0.24 nM) .
    MIP-1095
  • HY-12827
    Sortin1

    		Carboxypeptidase Others
    Sortin1 is a vacuolar protein sorting inhibitor that targets carboxypeptidase Y (CPY). Sortin1 is a soluble and membrane vacuolar marker molecule in plants and yeast .
    Sortin1
  • HY-129615
    MIP-1072

    		PSMA Cancer
    MIP-1072 is a small molecule specific prostate-specific membrane antigen (PSMA) inhibitor. MIP-1072 inhibits the glutamate carboxypeptidase activity of PSMA with an Ki value of 4.6 nM. MIP-1072 is promising for research of prostate cancer .
    MIP-1072
  • HY-100788R
    2-PMPA (Standard)

    2-(Phosphonomethyl)pentanedioic acid (Standard)

    		 Reference Standards Carboxypeptidase Neurological Disease
    2-PMPA (2-(Phosphonomethyl)pentanedioic acid) Standard is the analytical standard of 2-PMPA (HY-100788). This product is intended for research and analytical applications. 2-PMPA (2-(Phosphonomethyl)pentanedioic acid) sodium is a glutamate carboxypeptidase II (GCPII) inhibitor with an IC50 of 0.0003 μM. 2-PMPA sodium shows low blood-brain barrier penetration. 2-PMPA sodium blocks the hydrolysis of NAAG, regulates glutamate levels in the brain and neurovascular coupling. 2-PMPA sodium is applicable to the research of neurological diseases.
    2-PMPA (Standard)
  • HY-103345R
    2-MPPA (Standard)

    GPI-5693 (Standard)

    		 Reference Standards Carboxypeptidase Neurological Disease Cancer
    2-MPPA (Standard) is the analytical standard of 2-MPPA. This product is intended for research and analytical applications. 2-MPPA (GPI-5693) is an orally active and selective glutamate carboxypeptidase II (GCP II; PSMA) inhibitor with an IC50 of 90 nM .
    2-MPPA (Standard)
  • HY-129748
    SQ-24798

    		Carboxylesterase (CES) Others
    SQ-24,798 is a compound that inhibits carboxypeptidase B with high affinity and specificity. Its inhibitory effect may be achieved through the binding of the sulfhydryl group to the zinc ion of the enzyme and specific side chains.
    SQ-24798
  • HY-W044764R
    2-Benzylsuccinic acid (Standard)

    		Reference Standards Carboxypeptidase Neurological Disease Metabolic Disease
    2-Benzylsuccinic acid (DL-Benzylsuccinic acid) is an orally active carboxypeptidase A and Nna1 inhibitor. 2-Benzylsuccinic acid reduces cold hyperalgesia. 2-Benzylsuccinic acid can be used for the researches of neuropathic pain, non-alcoholic steatohepatitis .
    2-Benzylsuccinic acid (Standard)
  • HY-P3006
    Des-Leu10-angiotensin I

    		Drug Metabolite Cardiovascular Disease
    Des-Leu10-angiotensin I is a nonapeptide that inhibits rabbit lung angiotensin-converting enzyme peptidyl-dipeptide hydrolase with a Ki value of 31 μM, which is generated from angiotensin I by the action of carboxypeptidase-like activities residing in the human platelet and mast cell .
    Des-Leu10-angiotensin I
  • HY-165571
    E2072

    		Carboxypeptidase Neurological Disease
    E2072 is a selective, orally active competitive inhibitor of glutamate carboxypeptidase II (GCPII) with a Ki of 10 nM. E2072 alleviates established thermal hyperalgesia in a rat model of chronic constriction injury. E2072 prevents oxaliplatin-induced reductions in nerve conduction velocity and amplitude in mice. E2072 is applicable to research related to neuropathic pain and neuropathy .
    E2072
  • HY-N15140
    α-Thujaplicin

    		Drug Isomer Bacterial Fungal Carboxypeptidase Infection Cancer
    α-Thujaplicin, the isomer of Hinokitiol (HY-B2230), is an antimicrobial agent. α-Thujaplicin can be isolated from Aomori Hiba (Thujopsis dolabrata SIEB. et ZUCC. var. hondai MAKINO). α-Thujaplicin shows inhibition of Carboxypeptidase A (IC50: 32.4 μM). α-Thujaplicin shows rather strong antifungal activity against seven kinds of plant-pathogenic fungi, their MICs being in the range of 12.0-50.0 μg/mL. α-Thujaplicin shows clear antibacterial activity against Legionella pneumophila SG 1 and L. pneumophila SG 3, and their MICs are in the range of 12.5-50 μg/mL. α-Thujaplicin shows antibacterial activity against Enterococcus faecalis IFO-12965 with a MIC of 1.56 μg/mL. α-Thujaplicin shows germination inhibition toward the seed of Echinochloa utilis Ohwi et Yabuno. α-thujaplicin inhibits lymphocytic leukemia, stomach cancer, Ehrlich’s ascites carcinoma .
    α-Thujaplicin

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: